[go: up one dir, main page]

WO1995019777A3 - Utilisation de diesters de muramyl peptides, dans une forme orale, comme immunostimulants - Google Patents

Utilisation de diesters de muramyl peptides, dans une forme orale, comme immunostimulants Download PDF

Info

Publication number
WO1995019777A3
WO1995019777A3 PCT/FR1995/000077 FR9500077W WO9519777A3 WO 1995019777 A3 WO1995019777 A3 WO 1995019777A3 FR 9500077 W FR9500077 W FR 9500077W WO 9519777 A3 WO9519777 A3 WO 9519777A3
Authority
WO
WIPO (PCT)
Prior art keywords
diesters
oral form
muramyl peptides
immunostimulating agents
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR1995/000077
Other languages
English (en)
Other versions
WO1995019777A2 (fr
Inventor
Louis Chedid
Francoise Audibert
Pierre Lefrancier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vacsyn SA
Original Assignee
Vacsyn SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vacsyn SA filed Critical Vacsyn SA
Priority to JP7519390A priority Critical patent/JPH09509409A/ja
Priority to AU15809/95A priority patent/AU1580995A/en
Priority to EP95907694A priority patent/EP0741573A1/fr
Publication of WO1995019777A2 publication Critical patent/WO1995019777A2/fr
Publication of WO1995019777A3 publication Critical patent/WO1995019777A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pharmaceutique immunostimulante active par voie externe, caractérisée en ce qu'elle contient un diester de formule générale (I) dans laquelle: R est CH3, X est L-Ala ou L-Thr, R1 est un groupe hydrocarboné possédant de 1 à 4 atomes de carbone, R2 est un groupe hydrocarboné possédant 1 à 2 atomes de carbone, dans une formulation d'administration par voie externe compatible avec une administration de principe actif comprise entre 0,1 mg et 5 mg par kg de poids chez l'homme ou l'animal.
PCT/FR1995/000077 1994-01-25 1995-01-24 Utilisation de diesters de muramyl peptides, dans une forme orale, comme immunostimulants Ceased WO1995019777A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP7519390A JPH09509409A (ja) 1994-01-25 1995-01-24 経口型のムラミルペプチド・ジエステル
AU15809/95A AU1580995A (en) 1994-01-25 1995-01-24 Use of diesters of muramyl peptides in oral form as immunostimulating agents
EP95907694A EP0741573A1 (fr) 1994-01-25 1995-01-24 Utilisation de diesters de muramyl peptides, dans une forme orale, comme immunostimulants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9400786A FR2715305B1 (fr) 1994-01-25 1994-01-25 Diesters de muramyl peptides dans une forme orale.
FR94/00786 1994-01-25

Publications (2)

Publication Number Publication Date
WO1995019777A2 WO1995019777A2 (fr) 1995-07-27
WO1995019777A3 true WO1995019777A3 (fr) 1996-03-07

Family

ID=9459376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1995/000077 Ceased WO1995019777A2 (fr) 1994-01-25 1995-01-24 Utilisation de diesters de muramyl peptides, dans une forme orale, comme immunostimulants

Country Status (6)

Country Link
EP (1) EP0741573A1 (fr)
JP (1) JPH09509409A (fr)
AU (1) AU1580995A (fr)
CA (1) CA2181899A1 (fr)
FR (1) FR2715305B1 (fr)
WO (1) WO1995019777A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730935A1 (fr) * 1994-12-21 1996-08-30 Vacsyn Sa Vaccin presentant une immunogenicite accrue
FR2730936B1 (fr) * 1994-12-21 1997-10-31 Vacsyn Sa Vaccin presentant une immunogenicite accrue
FR2732604B1 (fr) * 1995-04-07 1997-06-06 Vacsyn Sa Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et compositions les contenant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153684A (en) * 1976-03-10 1979-05-08 Agence Nationale De Valorisation De La Recherche (Anvar) Immunizing and anti-infectious adjuvant agents constituted by N-acetyl-muramyl-L-alanyl-D-glutamic acid derivatives
EP0026746A1 (fr) * 1979-10-02 1981-04-08 Ciba-Geigy Ag Compositions combinées utilisables dans un procédé pour augmenter l'activité des antibiotiques, compositions antibiotiques ayant une efficacité accrue et procédé pour leur préparation
FR2672495A1 (fr) * 1991-02-08 1992-08-14 Vacsyn France Sa Compositions immunomodulatrices, a base de produits comportant au moins un groupe phosphate ou sulfate, et un gel d'un compose d'aluminium.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153684A (en) * 1976-03-10 1979-05-08 Agence Nationale De Valorisation De La Recherche (Anvar) Immunizing and anti-infectious adjuvant agents constituted by N-acetyl-muramyl-L-alanyl-D-glutamic acid derivatives
EP0026746A1 (fr) * 1979-10-02 1981-04-08 Ciba-Geigy Ag Compositions combinées utilisables dans un procédé pour augmenter l'activité des antibiotiques, compositions antibiotiques ayant une efficacité accrue et procédé pour leur préparation
FR2672495A1 (fr) * 1991-02-08 1992-08-14 Vacsyn France Sa Compositions immunomodulatrices, a base de produits comportant au moins un groupe phosphate ou sulfate, et un gel d'un compose d'aluminium.

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BREHMER, W. ET AL: "NONSPECIFIC IMMUNOSTIMULATION AGAINST AEROGENIC INFECTION OF TUBERCULOSIS AND INFLUENZA IN MICE BY SYNTHETIC MURAMYL DIPEPTIDE AND TREHALOSE DIMYCOLATE", INT. CON. SER.-EXCERPTA MED. (IMMUNOMODULATION MICROB. PROD. RELAT. SYNTH. COMPD.), vol. 563, pages 233 - 236 *
CHEDID, L. ET AL: "ENHANCEMENT OF NON-SPECIFIC IMMUNITY TO KLEBSIELLA PNEUMONIAE INFECTION BY A SYNTHETIC IMMUNOADJUVANT (N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE) AND SEVERAL ANALOGS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE USA, vol. 74, no. 5, pages 2089 - 2093 *
DENIS, M.: "IN VIVO MODULATION OF ATYPICAL MYCOBACTERIAL INFECTION: ADJUVANT THERAPY INCREASES RESISTANCE TO MYCOBACTERIUM AVIUM BY ENHANCING MACROPHAGE EFFECTOR FUNCTIONS", CELLULAR IMMUNOLOGY, vol. 134, no. 1, pages 42 - 53 *
JOHNSTON D. ET AL: "Effect of the adjuvant SAF-M on the immunogenicity of a murine B16 melanoma vaccine", VACCINE RES., 1993, 2/1 (55-64), USA *
MASIHI, K.N. ET AL: "EFFECT OF MURAMYL PEPTIDES ON REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS IN COMBINATION WITH ANTIRETROVIRALS", IXTH INTERNARIONAL CONFERENCE ON AIDS AND THE VITH INTERNATIONAL STD CONGRESS, BERLIN, pages 494 *
MASIHI, K.N. ET AL: "PROTECTIVE EFFECT OF MURAMYL DIPEPTIDE ANALOGS IN COMBINATION WITH TREHALOSE DIMYCOLATE AGAINST AEROGENIC INFLUENZA VIRUS AND MYCOBACTERIUM TUBERCULOSIS", JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, vol. 3, no. 6, pages 663 - 671 *
OHKAWA S. ET AL: "Immune responses induced by prototype vaccines for AIDS in rhesus monkeys", AIDS RES. HUM. RETROVIRUSES, 1994, 10/1 (27-38), USA *

Also Published As

Publication number Publication date
FR2715305B1 (fr) 1996-03-15
AU1580995A (en) 1995-08-08
FR2715305A1 (fr) 1995-07-28
JPH09509409A (ja) 1997-09-22
WO1995019777A2 (fr) 1995-07-27
EP0741573A1 (fr) 1996-11-13
CA2181899A1 (fr) 1995-07-27

Similar Documents

Publication Publication Date Title
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
CA2304704A1 (fr) Formulations et procedes de reduction de la toxicite d'agents antineoplasiques
CA2133177A1 (fr) Compositions de rapamycine pour administration orale
CA2233457A1 (fr) Compositions pharmaceutiques a base de dipeptide angiostatique et leur procede d'utilisation
HUP9901319A2 (hu) 9-Hidroxi-riszperidon zsírsavészterek vizes szuszpenziói, előállításuk és alkalmazásuk
MA26488A1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2203033A1 (fr) Composes et compositions pour l'administration d'agents actifs
WO1996007398A3 (fr) Liberation prolongee de peptides depuis des compositions pharmaceutiques
CA2133175A1 (fr) Compositions de rapamycine pour administration orale
BG103882A (en) Voriconazol-containing pharmaceutical compositions
ATE244015T1 (de) Formulierungen fuer faktor ix
HUP9900605A3 (en) Lipopolyamines as transfection agents, preparation and use thereof and pharmaceutical compositions containing them
AU8729791A (en) Pharmaceutical formulations
NZ244021A (en) Benzylthiazolidinedione derivatives, preparation and pharmaceutical compositions thereof
CA2426956A1 (fr) Compositions pharmaceutiques comprenant des derives d'ascomycine
CA2346001A1 (fr) Liberation regulee de compositions nanoparticulaires
BR9807076B1 (pt) "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
CA2360220A1 (fr) Composes a base d'oxadiazole et compositions destinees a l'apport d'agents actifs
NZ318282A (en) Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
BR0012429A (pt) Fórmulações para il-11
CA2254079A1 (fr) Derives de l'androstene
CS545686A1 (en) Farmaceuticky prostredek a antihepatotoxickym pusobenim
CA2112907A1 (fr) Peptide eliminant la toxicite du tnf et/ou du lps
CA2173147A1 (fr) Agent anti-obesite
CA2078662A1 (fr) Derive de 4-desoxy-epipodophyllotoxine ou sel pharmaceutiquement acceptable

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2181899

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995907694

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1996 682612

Country of ref document: US

Date of ref document: 19961016

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995907694

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995907694

Country of ref document: EP